申请人:Pfizer Limited
公开号:EP0232025A2
公开(公告)日:1987-08-12
1,4-Dihydropyridine derivatives of the formula:-
wherein R is an aryl or heteroaryl group; R¹ and R² are each independently C₁-C₄ alkyl optionally substituted by C₃-C₇ cycloalkyl, aryl, CF₃, C₂-C₄ alkanoyl, halo, hydroxy, cyano, C₁-C₄ alkoxy, C₂-C₄ alkanoyloxy or NR³R⁴ where R³ and R⁴ are each independently H, C₁-C₄ alkyl, aryl-(C₁-C₄ alkyl) or together with the nitrogen atom to which they are attached represent a pyrrolidinyl, piperidino, morpholino, piperazinyl, 4-(C₁-C₄ alkyl)piperazin-1-yl or 4-formylpiperazin-1-yl group; m is 0, 1 or 2; Y is an optional alkylene linking group of from 0 to 4 carbon atoms which may be branched; and Z is Het, -O-Het or -NH-Het where Het is an optionally substituted heterocyclic group, are calcium channel blockers useful as anti-ischaemic and antihypertensive agents.
式中的 1,4-二氢吡啶衍生物
其中 R 是芳基或杂芳基;R¹ 和 R² 各自独立地为 C₁-C₄ 烷基,可任选被 C₃-C₇ 环烷基、芳基、CF₃、C₂-C₄ 烷酰基取代、卤素、羟基、氰基、C₁-C₄ 烷氧基、C₂-C₄ 烷酰氧基或 NR³R⁴ 其中 R³ 和 R⁴ 各自独立地为 H、C₁-C₄烷基、芳基-(C₁-C₄烷基)或与所连接的氮原子一起代表吡咯烷基、哌啶基、吗啉基、哌嗪基、4-(C₁-C₄烷基)哌嗪-1-基或 4-甲酰基哌嗪-1-基基团;m 是 0、1 或 2;Y 是 0 至 4 个碳原子的任选亚烷基连接基团,可以是支链;Z 是 Het、-O-Het 或 -NH-Het,其中 Het 是任选取代的杂环基团。